Exhibit 4.5


 


DESCRIPTION
OF REGISTRANT’S SECURITIES


 


The following summary of the material terms of
the securities of Kismet One Acquisition Corp, a company incorporated in the British Virgin Islands, is not intended to be a complete
summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum
and articles of association and the warrant agreement, dated August 5, 2020, between the company and Continental Stock Transfer &
Trust Company (the “Warrant Agreement”), in each case incorporated by reference as exhibits to the company’s Annual
Report on Form 10-K for the year ended December 31, 2020 (the “Report”), and applicable British Virgin Islands law. We urge
you to read our amended and restated memorandum and articles of association and the Warrant Agreement in their entirety for a complete
description of the rights and preferences of our securities.


 


Certain Terms


 


In this document, unless the
context otherwise requires, references to:


 


	 	●	“we,” “us,” “company,” “our company” or “Kismet” are to Kismet Acquisition One Corp, a business company incorporated in the British Virgin Islands with limited liability;


 


	 	●	“BVI” refers to the British Virgin Islands;


 


	 	●	“Companies Act” and “Insolvency Act” are to the British Virgin Islands Business Companies Act, 2004 and the Insolvency Act, 2003, of the British Virgin Islands, respectively, and in each case, as amended;


 


	 	●	“forward purchase agreement” are to an agreement providing for the sale of forward purchase units to our sponsor in a private placement to occur concurrently with the closing of our initial business combination which agreement was superseded by the A&R Forward Purchase Agreement (defined below);


 


	 	●	“forward purchase securities” are to the forward purchase units, the forward purchase shares and the forward purchase warrants;


 


	 	●	“forward purchase shares” are to ordinary shares underlying the forward purchase units and the forward purchase warrants;


 


	 	●	“forward purchase units” are to the units to be sold pursuant to the forward purchase agreement;


 


	 	●	“forward purchase warrants” are to warrants to purchase ordinary shares underlying the forward purchase units;


 


	 	●	“founder shares” refer to our ordinary shares initially purchased by our sponsor in a private placement prior to our initial public offering;


 


	 	●	“management” or our “management team” are to our executive officers and directors;


 


	 	●	“ordinary shares” refer to the ordinary shares of no par value in the company;


 


	 	●	“private placement warrants” are to the warrants we sold to our sponsor in a private placement simultaneously with the closing of the initial public offering;


 


	 	●	“public shares” and “public warrants” refer to ordinary shares and warrants which were sold as part of the units in our initial public offering (whether they were purchased in the initial public offering or thereafter in the open market); and


 


	 	●	“public shareholders” and “public warrant holders” refer to the holders of our public shares and public warrants


 






     


     


    

 


General


 


We are a company incorporated in the British Virgin
Islands as a business company (Company Number 2037458) and our affairs are governed by our amended and restated memorandum and articles
of association, the Companies Act and the common law of the British Virgin Islands. We are authorized to issue an unlimited number of
both ordinary shares of no par value and preferred shares of no par value. As of the date of the Report, 31,750,000 ordinary shares are
outstanding and no preferred shares area outstanding.


 


Units


 


Each unit consists of one ordinary share and one-half of
one warrant. Each whole warrant entitles the holder thereof to purchase one ordinary share at a price of $11.50 per share, subject to
adjustment as more fully described in our final prospectus. Pursuant to the warrant agreement, a warrant holder may exercise its warrants
only for a whole number of ordinary shares. This means that only a whole warrant may be exercised at any given time by a warrant holder.
Holders will need to have their brokers contact our transfer agent in order to separate the units into ordinary shares and warrants. No
fractional warrants will be issued upon separation of the units and only whole units will trade. The ordinary shares and warrants underlying
the units began to trade separately on September 28, 2020, and holders have the option to continue to hold units or separate their units
into the component securities.


 


Ordinary Shares


 


As of March 25, 2021, there were 31,750,000 ordinary
shares outstanding, all of which were held of record by our sponsor.


 


Under the Companies Act, the ordinary shares are
deemed to be issued when the name of the shareholder is entered in our register of members. Our register of members is maintained by our
transfer agent Continental Stock Transfer & Trust Company, which entered the name of Cede & Co. in our register
of members on the consummation of our initial public offering as nominee for each of the respective shareholders. If (a) information
that is required to be entered in the register of members is omitted from the register or is inaccurately entered in the register, or
(b) there is unreasonable delay in entering information in the register, a shareholder of the company, or any person who is aggrieved
by the omission, inaccuracy or delay, may apply to the British Virgin Islands courts for an order that the register be rectified, and
the court may either refuse the application or order the rectification of the register, and may direct the company to pay all costs of
the application and any damages the applicant may have sustained.


 


At any general meeting on a show of hands every
ordinary shareholder who is present in person (or, in the case of a shareholder being a corporation, by its duly authorized representative)
or by proxy will have one vote for each share held on all matters to be voted on by shareholders. Voting at any meeting of the ordinary
shareholders is by show of hands unless a poll is demanded. A poll may be demanded by shareholders present in person or by proxy if the
shareholder disputes the outcome of the vote on a proposed resolution and the chairman shall cause a poll to be taken. Prior to the consummation
of our initial business combination, the rights attaching to ordinary shares and certain other provisions relating to our pre-initial business
combination activities may only be amended by a resolution of shareholders holding 65% of the ordinary shares attending and voting at
the relevant meeting. Following the consummation of, or in connection with, our initial business combination, the rights and obligations
attaching to our ordinary shares and other provisions of our amended and restated memorandum and articles of association may be amended
if approved by 65% of the votes of shareholders attending and voting on such amendment or by resolution of the directors. Our board of
directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors
being elected in each year. There is no cumulative voting with respect to the election of directors, with the result that the holders
of more than 50% of the shares voted for the election of directors can elect all of the directors. Our shareholders are entitled to receive
ratable dividends when, as and if declared by the board of directors out of funds legally available therefor.


 


In accordance with the corporate governance requirements
of Nasdaq Capital Market (“Nasdaq”), we are not required to hold an annual meeting until one year after our first fiscal year
end following our listing on Nasdaq. Therefore, we may not hold an annual meeting of shareholders until after we consummate our initial
business combination. Therefore, if our shareholders want us to hold a meeting prior to such consummation, they may requisition the directors
to hold one upon the written request of members entitled to exercise at least 30 percent of the voting rights in respect of the matter
for which the meeting is requested. Under British Virgin Islands law, we may not increase the required percentage to call a meeting above
such 30 percent level.


 






    2


     


    

 


We will provide our shareholders with the opportunity
to redeem all or a portion of their public shares upon the completion of our initial business combination at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of our initial
business combination including interest earned on the funds held in the trust account and not previously released to us to pay our taxes,
if any, divided by the number of then outstanding public shares, subject to the limitations described herein. The amount in the trust
account was initially $250,000,000. The per-share amount we will distribute to investors who properly redeem their shares will not
be reduced by the deferred underwriting commissions we will pay to the underwriter. Our sponsor, officers and directors have entered into
respective letter agreements with us, pursuant to which our sponsor has agreed to waive its redemption rights with respect to its founder
shares, and our sponsor, officers and directors have agreed to waive their redemption rights with respect to any public shares they may
have acquired during or after our initial public offering, in connection with the completion of our initial business combination. Unlike
many blank check companies that hold shareholder votes and conduct proxy solicitations in conjunction with their initial business combinations
and provide for related redemptions of public shares for cash upon completion of such initial business combinations even when a vote is
not required by law, if a shareholder vote is not required by law and we do not decide to hold a shareholder vote for business or other
legal reasons, we will, pursuant to our amended and restated memorandum and articles of association, conduct the redemptions pursuant
to the tender offer rules of the SEC, and file tender offer documents with the SEC prior to completing our initial business combination.
Our amended and restated memorandum and articles of association require these tender offer documents to contain substantially the same
financial and other information about the initial business combination and the redemption rights as is required under the SEC’s
proxy rules. If, however, a shareholder approval of the transaction is required by law, or we decide to obtain shareholder approval for
business or other legal reasons, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation
pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial
business combination only if a majority of the outstanding ordinary shares voted are voted in favor of the business combination. However,
the participation of our sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions, if any,
could result in the approval of our initial business combination even if a majority of our public shareholders vote, or indicate their
intention to vote, against such business combination. For purposes of seeking approval of the majority of our outstanding ordinary shares,
non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. We intend to give approximately
30 days (but not less than 10 days nor more than 60 days) prior written notice of any such meeting, if required, at which
a vote shall be taken to approve our initial business combination.


 


If we seek shareholder approval of our initial business
combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules,
our amended and restated memorandum and articles of association provide that a public shareholder, together with any affiliate of such
shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with
respect to more than an aggregate of 20% of the shares sold in the initial public offering, which we refer to as the Excess Shares. However,
we would not be restricting our shareholders’ ability to vote all of their shares (including Excess Shares) for or against our initial
business combination. Our shareholders’ inability to redeem the Excess Shares will reduce their influence over our ability to complete
our initial business combination, and such shareholders could suffer a material loss in their investment if they sell such Excess Shares
on the open market. Additionally, such shareholders will not receive redemption distributions with respect to the Excess Shares if we
complete our initial business combination. And, as a result, such shareholders will continue to hold that number of shares exceeding 20%
and, in order to dispose of such shares would be required to sell their shares in open market transactions, potentially at a loss.


 


If we seek shareholder approval in connection with
our initial business combination, our sponsor has agreed to vote its founder shares and any public shares purchased during or after our
initial public offering in favor of our initial business combination. Additionally, each public shareholder may elect to redeem their
public shares irrespective of whether they vote for or against the proposed transaction.


 






    3


     


    

 


Pursuant to our amended and restated memorandum
and articles of association, if we are unable to complete our initial business combination by August 10, 2022, we will (i) cease
all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter
subject to lawfully available funds therefor, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released
to us to pay our taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding
public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive
further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of our remaining shareholders and our board of directors, proceed to commence a voluntary liquidation
and thereby a formal dissolution of the company, subject in each case to our obligations to provide for claims of creditors and the requirements
of the laws of the British Virgin Islands and other applicable law. Our sponsor has entered into a letter agreement with us, pursuant
to which it has agreed to waive its rights to liquidating distributions from the trust account with respect to its founder shares if we
fail to complete our initial business combination by August 10, 2022. However, if our sponsor acquires public shares after our initial
public offering, it will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail
to complete our initial business combination within the prescribed time period.


 


In the event of a liquidation, dissolution or winding
up of the company after an initial business combination, our shareholders are entitled to share ratably in all assets remaining available
for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over
the ordinary shares. Our shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable
to the ordinary shares, except that we will provide our shareholders with the redemption rights set forth above.


 


Founder Shares


 


The founder shares are identical to the ordinary
shares included in the units sold in our initial public offering, and the holder of founder shares has the same shareholder rights as
public shareholders, except that (i) the founder shares are subject to certain transfer restrictions, as described in more detail
below, and (ii) our sponsor has entered into a letter agreement with us, pursuant to which it has agreed (A) to waive its redemption
rights with respect to its founder shares and public shares in connection with the completion of our initial business combination and
(B) to waive its rights to liquidating distributions from the trust account with respect to its founder shares if we fail to complete
our initial business combination by August 10, 2022, although it will be entitled to liquidating distributions from the trust account
with respect to any public shares it holds if we fail to complete our initial business combination within such time period. If we submit
our initial business combination to our public shareholders for a vote, our sponsor has agreed to vote its founder shares and any public
shares purchased during or after our initial public offering in favor of our initial business combination. In addition, our officers and
directors have agreed to (i) waive their redemption rights with respect to their public shares purchased during or after our initial public
offering in connection with the completion of our initial business combination and (ii) vote any public shares owned by them immediately
before our initial public offering as well as any public shares acquired in our initial public offering or in the aftermarket in favor
of our initial business combination.


 


Our sponsor has agreed not to transfer, assign or
sell any of the founder shares (except to certain permitted transferees as described below) until the earlier of (x) one year after
the date of the completion of our initial business combination or earlier if, subsequent to our initial business combination, the last
reported sale price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations
and recapitalizations) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial
business combination, or (y) we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results
in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. The founder shares
are identical to the ordinary shares included in the units sold in our initial public offering. However, our sponsor has agreed (A) to
vote any shares owned by it in favor of any proposed business combination and (B) not to redeem any shares in connection with a shareholder
vote or tender offer to approve or in connection with a proposed initial business combination.


 






    4


     


    

 


Preferred Shares


 


Our amended and restated memorandum and articles
of association authorizes the creation and issuance without shareholder approval of an unlimited number of preferred shares divided into
five classes, Class A through Class E each with such designation, rights and preferences as may be determined by a resolution
of our board of directors to amend the amended and restated memorandum and articles of association to create such designations, rights
and preferences. We have five classes of preferred shares to give us flexibility as to the terms on which each Class is issued. Unlike
Delaware law, all shares of a single class must be issued with the same rights and obligations. Accordingly, starting with five classes
of preference shares allows us to issue shares at different times on different terms. No preferred shares are currently issued or outstanding.
Accordingly, our board of directors is empowered, without shareholder approval, to issue preferred shares with dividend, liquidation,
redemption, voting or other rights which could adversely affect the voting power or other rights of the holders of ordinary shares. However,
the underwriting agreement, dated August 5, 2020, prohibits us, prior to our initial business combination, from issuing preferred shares
which participate in any manner in the proceeds of the trust account, or which vote as a class with the ordinary shares on our initial
business combination. We may issue some or all of the preferred shares to effect our initial business combination. In addition, the preferred
shares could be utilized as a method of discouraging, delaying or preventing a change in control of us. Although we do not currently intend
to issue any preferred shares, we may do so in the future.


 


The rights of preferred shareholders, once the preferred
shares are in issue, may only be amended by a resolution to amend our amended and restated memorandum and articles of association provided
such amendment is also approved by a separate resolution of a majority of the votes of preferred shareholders who being so entitled attend
and vote at the class meeting of the relevant preferred class. If our preferred shareholders want us to hold a meeting of preferred shareholders
(or of a class of preferred shareholders), they may requisition the directors to hold one upon the written request of preferred shareholders
entitled to exercise at least 30 percent of the voting rights in respect of the matter (or class) for which the meeting is requested.
Under British Virgin Islands law, we may not increase the required percentage to call a meeting above 30 percent.


 


Under the Companies Act there are no provisions
which specifically prevent the issuance of preferred shares or any such other ‘poison pill’ measures. Our amended and restated
memorandum and articles of association also do not contain any express prohibitions on the issuance of any preferred shares. Therefore,
the directors, without the approval of the holders of ordinary shares, may issue preferred shares that have characteristics that may be
deemed to be anti-takeover. Additionally, such a designation of shares may be used in connection with plans that are poison pill plans.
However, as noted above under the Companies Act, a director in the exercise of his powers and performance of his duties is required to
act honestly and in good faith in what the director believes to be the best interests of the company.


 


Warrants


 


Public Warrants and Forward Purchase Warrants


 


Each whole warrant entitles the registered holder
to purchase one ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on the
later of August 10, 2021 or 30 days after the completion of our initial business combination. Pursuant to the warrant agreement,
a warrant holder may exercise its warrants only for a whole number of ordinary shares. This means that only a whole warrant may be exercised
at any given time by a warrant holder. The warrants will expire five years after the date on which they first became exercisable, at 5:00 p.m.,
New York City time, or earlier upon redemption or liquidation.


 


We will not be obligated to deliver any ordinary
shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement
under the Securities Act of 1933, as amended (the “Securities Act”) with respect to the ordinary shares underlying the warrants
is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect
to registration, or a valid exemption from registration is available. No warrant will be exercisable and we will not be obligated to issue
ordinary shares upon exercise of a warrant unless the ordinary shares issuable upon such warrant exercise have been registered, qualified
or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that
the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will
not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net
cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit
containing such warrant will have paid the full purchase price for the unit solely for the ordinary share underlying such unit.


 






    5


     


    

 


We have agreed that as soon as practicable, but
in no event later than 15 business days, after the closing of our initial business combination, we will use our commercially reasonable
efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the ordinary shares issuable
upon exercise of the warrants. We will use our commercially reasonable efforts to cause the same to become effective and to maintain the
effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance
with the provisions of the warrant agreement. Notwithstanding the above, if our ordinary shares are at the time of any exercise of a warrant
not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1)
of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a “cashless
basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file
or maintain in effect a registration statement or register or qualify the shares under applicable blue sky laws to the extent an exemption
is available. In such event, each holder would pay the exercise price by surrendering each such warrant for that number of ordinary shares
equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of our ordinary shares underlying the warrants,
multiplied by the excess of the “fair market value” less the exercise price of the warrants by (y) the fair market value and
(B) 0.361. The “fair market value” shall mean the volume weighted average price of our ordinary shares for the 10 trading
days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.


 


Redemption of warrants when the price per ordinary
share equals or exceeds $18.00. Once the warrants become exercisable, we may redeem the outstanding warrants (except as described
herein with respect to the private placement warrants):


 


		●	in whole and not in part;



 


		●	at a price of $0.01 per warrant;



 


		●	upon not less than 30 days’ prior written notice
of redemption to each warrant holder; and



 


		●	if, and only if, the last reported sale price of the ordinary
shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise
price of



 


a warrant as described under the heading “— Warrants
— Public Warrants and Forward Purchase Warrants — Anti-dilution Adjustments”) for any 20 trading days within a
30-trading day period ending three business days before we send the notice of redemption to the warrant holders (which we refer to
as the “Reference Value”).


 


We will not redeem the warrants as described above
unless a registration statement under the Securities Act covering the issuance of the ordinary shares issuable upon exercise of the warrants
is then effective and a current prospectus relating to those ordinary shares is available throughout the 30-day redemption period.
If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the
underlying securities for sale under all applicable state securities laws.


 


We have established the last of the redemption criterion
discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price.
If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to
exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the ordinary shares may fall below the
$18.00 redemption trigger price (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations
and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.


 


Redemption of warrants when the price per ordinary
share equals or exceeds $10.00. Once the warrants become exercisable, we may redeem the outstanding warrants:


 


		●	in whole and not in part;



 


		●	at $0.10 per warrant upon a minimum of 30 days’
prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis
prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the
“fair market value” of our ordinary shares (as defined below) except as otherwise described below;



 






    6


     


    

 


		●	if, and only if, the Reference Value (as defined above under
“Redemption of warrants when the price per ordinary share equals or exceeds $18.00”) equals or exceeds $10.00 per public
share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under
the heading “— Warrants — Public Warrants and Forward Purchase Warrants —Anti-dilution Adjustments”);
and



 


		●	if the Reference Value is less than $18.00 per share (as
adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading
“— Warrants — Public Warrants and Forward Purchase Warrants — Anti-dilution Adjustments”), the private
placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described
above.



 


During the period beginning on the date the notice
of redemption is given, holders may elect to exercise their warrants on a cashless basis. The numbers in the table below represent the
number of ordinary shares that a warrant holder will receive upon such cashless exercise in connection with a redemption by us pursuant
to this redemption feature, based on the “fair market value” of our ordinary shares on the corresponding redemption date (assuming
holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined for these purposes based
on volume weighted average price of our ordinary shares during the 10 trading days immediately following the date on which the notice
of redemption is sent to the holders of warrants, and the number of months that the corresponding redemption date precedes the expiration
date of the warrants, each as set forth in the table below. We will provide our warrant holders with the final fair market value no later
than one business day after the 10-trading day period described above ends.


 


Pursuant to the warrant agreement, references above
to ordinary shares shall include a security other than ordinary shares into which the ordinary shares have been converted or exchanged
for in the event we are not the surviving company in our initial business combination. The numbers in the table below will not be adjusted
when determining the number of ordinary shares to be issued upon exercise of the warrants if we are not the surviving entity following
our initial business combination.


 






    7


     


    




 


The share prices set forth in the column headings
of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a warrant or the exercise price
of the warrant is adjusted as set forth under the heading “— Anti-dilution Adjustments” below. If the number
of shares issuable upon exercise of a warrant is adjusted, the adjusted share prices in the column headings will equal the share prices
immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the exercise price of the warrant after such
adjustment and the denominator of which is the price of the warrant immediately prior to such adjustment. In such an event, the number
of shares in the table below shall be adjusted by multiplying such share amounts by a fraction, the numerator of which is the number of
shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of which is the number of shares
deliverable upon exercise of a warrant as so adjusted. If the exercise price of the warrant is adjusted as a result of raising capital
in connection with the initial business combination, the adjusted stock prices in the column headings will by multiplied by a fraction,
the numerator of which is the higher of the Market Value and the Newly Issued Price as set forth under the heading “— Anti-dilution Adjustments”
and the denominator of which is $10.00.


 


	 	 	Fair Market Value of Ordinary Shares	 
	Redemption Date
 (period to expiration of warrants)	 	 	≤10.00	 	 	 	11.00	 	 	 	12.00	 	 	 	13.00	 	 	 	14.00	 	 	 	15.00	 	 	 	16.00	 	 	 	17.00	 	 	 	≥18.00	 
	60 months	 	 	0.261	 	 	 	0.281	 	 	 	0.297	 	 	 	0.311	 	 	 	0.324	 	 	 	0.337	 	 	 	0.348	 	 	 	0.358	 	 	 	0.361	 
	57 months	 	 	0.257	 	 	 	0.277	 	 	 	0.294	 	 	 	0.310	 	 	 	0.324	 	 	 	0.337	 	 	 	0.348	 	 	 	0.358	 	 	 	0.361	 
	54 months	 	 	0.252	 	 	 	0.272	 	 	 	0.291	 	 	 	0.307	 	 	 	0.322	 	 	 	0.335	 	 	 	0.347	 	 	 	0.357	 	 	 	0.361	 
	51 months	 	 	0.246	 	 	 	0.268	 	 	 	0.287	 	 	 	0.304	 	 	 	0.320	 	 	 	0.333	 	 	 	0.346	 	 	 	0.357	 	 	 	0.361	 
	48 months	 	 	0.241	 	 	 	0.263	 	 	 	0.283	 	 	 	0.301	 	 	 	0.317	 	 	 	0.332	 	 	 	0.344	 	 	 	0.356	 	 	 	0.361	 
	45 months	 	 	0.235	 	 	 	0.258	 	 	 	0.279	 	 	 	0.298	 	 	 	0.315	 	 	 	0.330	 	 	 	0.343	 	 	 	0.356	 	 	 	0.361	 
	42 months	 	 	0.228	 	 	 	0.252	 	 	 	0.274	 	 	 	0.294	 	 	 	0.312	 	 	 	0.328	 	 	 	0.342	 	 	 	0.355	 	 	 	0.361	 
	39 months	 	 	0.221	 	 	 	0.246	 	 	 	0.269	 	 	 	0.290	 	 	 	0.309	 	 	 	0.325	 	 	 	0.340	 	 	 	0.354	 	 	 	0.361	 
	36 months	 	 	0.213	 	 	 	0.239	 	 	 	0.263	 	 	 	0.285	 	 	 	0.305	 	 	 	0.323	 	 	 	0.339	 	 	 	0.353	 	 	 	0.361	 
	33 months	 	 	0.205	 	 	 	0.232	 	 	 	0.257	 	 	 	0.280	 	 	 	0.301	 	 	 	0.320	 	 	 	0.337	 	 	 	0.352	 	 	 	0.361	 
	30 months	 	 	0.196	 	 	 	0.224	 	 	 	0.250	 	 	 	0.274	 	 	 	0.297	 	 	 	0.316	 	 	 	0.335	 	 	 	0.351	 	 	 	0.361	 
	27 months	 	 	0.185	 	 	 	0.214	 	 	 	0.242	 	 	 	0.268	 	 	 	0.291	 	 	 	0.313	 	 	 	0.332	 	 	 	0.350	 	 	 	0.361	 
	24 months	 	 	0.173	 	 	 	0.204	 	 	 	0.233	 	 	 	0.260	 	 	 	0.285	 	 	 	0.308	 	 	 	0.329	 	 	 	0.348	 	 	 	0.361	 
	21 months	 	 	0.161	 	 	 	0.193	 	 	 	0.223	 	 	 	0.252	 	 	 	0.279	 	 	 	0.304	 	 	 	0.326	 	 	 	0.347	 	 	 	0.361	 
	18 months	 	 	0.146	 	 	 	0.179	 	 	 	0.211	 	 	 	0.242	 	 	 	0.271	 	 	 	0.298	 	 	 	0.322	 	 	 	0.345	 	 	 	0.361	 
	15 months	 	 	0.130	 	 	 	0.164	 	 	 	0.197	 	 	 	0.230	 	 	 	0.262	 	 	 	0.291	 	 	 	0.317	 	 	 	0.342	 	 	 	0.361	 
	12 months	 	 	0.111	 	 	 	0.146	 	 	 	0.181	 	 	 	0.216	 	 	 	0.250	 	 	 	0.282	 	 	 	0.312	 	 	 	0.339	 	 	 	0.361	 
	9 months	 	 	0.090	 	 	 	0.125	 	 	 	0.162	 	 	 	0.199	 	 	 	0.237	 	 	 	0.272	 	 	 	0.305	 	 	 	0.336	 	 	 	0.361	 
	6 months	 	 	0.065	 	 	 	0.099	 	 	 	0.137	 	 	 	0.178	 	 	 	0.219	 	 	 	0.259	 	 	 	0.296	 	 	 	0.331	 	 	 	0.361	 
	3 months	 	 	0.034	 	 	 	0.065	 	 	 	0.104	 	 	 	0.150	 	 	 	0.197	 	 	 	0.243	 	 	 	0.286	 	 	 	0.326	 	 	 	0.361	 
	0 months	 	 	—	 	 	 	—	 	 	 	0.042	 	 	 	0.115	 	 	 	0.179	 	 	 	0.233	 	 	 	0.281	 	 	 	0.323	 	 	 	0.361	 




 








    8


     


    

 


The exact fair market value and redemption date
may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption
date is between two redemption dates in the table, the number of ordinary shares to be issued for each warrant exercised will be determined
by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier
and later redemption dates, as applicable, based on a 365 or 366-day year, as applicable. For example, if the volume weighted
average price of our ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent
to the holders of the warrants is $11.00 per share, and at such time there are 57 months until the expiration of the warrants, holders
may choose to, in connection with this redemption feature, exercise their warrants for 0.277 ordinary shares for each whole warrant. For
an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume weighted average
price of our ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the
holders of the warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants, holders may
choose to, in connection with this redemption feature, exercise their warrants for 0.298 ordinary shares for each whole warrant. In no
event will the warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.361 ordinary shares
per warrant (subject to adjustment). Finally, as reflected in the table above, if the warrants are out of the money and about to expire,
they cannot be exercised on a cashless basis in connection with a redemption by us pursuant to this redemption feature, since they will
not be exercisable for any ordinary shares.


 


This redemption feature differs from the typical
warrant redemption features used in many other blank check offerings, which typically only provide for a redemption of warrants for cash
(other than the private placement warrants) when the trading price for the ordinary shares exceeds $18.00 per share for a specified period
of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the ordinary shares are
trading at or above $10.00 per public share, which may be at a time when the trading price of our ordinary shares is below the exercise
price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without the
warrants having to reach the $18.00 per share threshold set forth above under “— Redemption of warrants when the price
per ordinary share equals or exceeds $18.00.” Holders choosing to exercise their warrants in connection with a redemption pursuant
to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model with a fixed volatility
input as of August 5, 2020. This redemption right provides us with an additional mechanism by which to redeem all of the outstanding warrants,
and therefore have certainty as to our capital structure as the warrants would no longer be outstanding and would have been exercised
or redeemed. We will be required to pay the applicable redemption price to warrant holders if we choose to exercise this redemption right
and it will allow us to quickly proceed with a redemption of the warrants if we determine it is in our best interest to do so. As such,
we would redeem the warrants in this manner when we believe it is in our best interest to update our capital structure to remove the warrants
and pay the redemption price to the warrant holders.


 


As stated above, we can redeem the warrants when
the ordinary shares are trading at a price starting at $10.00, which is below the exercise price of $11.50, because it will provide certainty
with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants
on a cashless basis for the applicable number of shares. If we choose to redeem the warrants when the ordinary shares are trading at a
price below the exercise price of the warrants, this could result in the warrant holders receiving fewer ordinary shares than they would
have received if they had chosen to wait to exercise their warrants for ordinary shares if and when such ordinary shares were trading
at a price higher than the exercise price of $11.50.


 






    9


     


    

 


No fractional ordinary shares will be issued upon
exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest
whole number of the number of ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable
for a security other than the ordinary shares pursuant to the warrant agreement (for instance, if we are not the surviving company in
our initial business combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for
a security other than the ordinary shares, we (or surviving company) will use our commercially reasonable efforts to register under the
Securities Act the security issuable upon the exercise of the warrants.


 


Redemption Procedures.    A
holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s
affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder)
of the ordinary shares outstanding immediately after giving effect to such exercise.


 


Anti-dilution Adjustments.    If
the number of outstanding ordinary shares is increased by a dividend payable in ordinary shares, or by a split-up of ordinary shares
or other similar event, then, on the effective date of such share dividend, split-up or similar event, the number of ordinary shares
issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering
to holders of ordinary shares entitling holders to purchase ordinary shares at a price less than the fair market value will be deemed
a share dividend of a number of ordinary shares equal to the product of (i) the number of ordinary shares actually sold in such rights
offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for ordinary
shares) multiplied by (ii) one (1) minus the quotient of (x) the price per share of ordinary shares paid in such rights
offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into
or exercisable for ordinary shares, in determining the price payable for ordinary shares, there will be taken into account any consideration
received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the
volume weighted average price of ordinary shares as reported during the ten (10) trading day period ending on the trading day prior
to the first date on which the ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the
right to receive such rights.


 


In addition, if we, at any time while the warrants
are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of ordinary shares
on account of such ordinary shares (or other shares of our share capital into which the warrants are convertible), other than (a) as
described above, (b) any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends
and cash distributions paid on the ordinary shares during the 365-day period ending on the date of declaration of such dividend or
distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions
that resulted in an adjustment to the exercise price or to the number of ordinary shares issuable on exercise of each warrant) but only
with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c) to satisfy
the redemption rights of the holders of ordinary shares in connection with a proposed initial business combination, (d) to satisfy
the redemption rights of the holders of ordinary shares in connection with a shareholder vote to amend our amended and restated memorandum
and articles of association (A) to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete
our initial business combination by August 10, 2022 or (B) with respect to any other provision relating to shareholders’ rights
or pre-initial business combination activity, or (e) in connection with the redemption of our public shares upon our failure
to complete our initial business combination, then the warrant exercise price will be decreased, effective immediately after the effective
date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each ordinary share in
respect of such event.


 






    10


     


    

 


If the number of outstanding ordinary shares is
decreased by a consolidation, combination, reverse share split or reclassification of ordinary shares or other similar event, then, on
the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of ordinary
shares issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding ordinary shares.


 


Whenever the number of ordinary shares purchasable
upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant
exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of ordinary shares
purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator of which will be the
number of ordinary shares so purchasable immediately thereafter.


 


In addition, if (x) we issue additional ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination
at an issue price or effective issue price of less than $9.20 per share of our ordinary shares (with such issue price or effective issue
price to be determined in good faith by our board of directors and, in the case of any such issuance to our sponsor or an affiliate of
our sponsor, without taking into account any founder shares held by our sponsor or an affiliate of our sponsor, as applicable, prior to
such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of
the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the completion
of our initial business combination (net of redemptions), and (z) the volume-weighted average trading price of our ordinary shares
during the 20 trading day period starting on the trading day prior to the day on which we complete our initial business combination (such
price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent)
to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger
prices described adjacent to “Redemption of warrants when the price per ordinary share equals or exceeds $18.00” and “Redemption
of warrants when the price per ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 100%
and 180% of the higher of the Market Value and the Newly Issued Price, respectively.


 


In case of any reclassification or reorganization
of the outstanding ordinary shares (other than those described above or that solely affects the par value of such ordinary shares), or
in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are
the continuing corporation and that does not result in any reclassification or reorganization of our outstanding ordinary shares), or
in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially
as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive,
upon the basis and upon the terms and conditions specified in the warrants and in lieu of the ordinary shares immediately theretofore
purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares or other securities or property
(including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such
sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to
such event. If less than 70% of the consideration receivable by the holders of ordinary shares in such a transaction is payable in the
form of shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market,
or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises
the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified
in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such
exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction occurs during the
exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the
warrants.


 


The warrants were issued in registered form under
a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. You should review a copy of
the warrant agreement, which is filed as an exhibit to this Report, for a complete description of the terms and conditions applicable
to the warrants. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder for the
purpose of (i) curing any ambiguity or to correct any mistake, including to conform the provisions of the warrant agreement to the description
of the terms of the warrants and the warrant agreement set forth in the final prospectus, or defective provision or (ii) adding or changing
any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem
necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the warrants, provided
that the approval by the holders of at least 65% of the then-outstanding public warrants is required to make any change that adversely
affects the interests of the registered holders.


 






    11


     


    

 


The warrants may be exercised upon surrender of
the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse
side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless
basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders
do not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their warrants and receive
ordinary shares. After the issuance of ordinary shares upon exercise of the warrants, each holder will be entitled to one vote for each
share held of record on all matters to be voted on by shareholders.


 


Warrants may be exercised only for a whole number
of ordinary shares. No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would
be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of ordinary shares
to be issued to the warrant holder.


 


Private Placement Warrants


 


The private placement warrants (including the ordinary
shares issuable upon exercise of the private placement warrants) are not transferable, assignable or saleable (except, among other limited
exceptions as described in our final prospectus under “Principal Shareholders — Transfer Restrictions on Founder
Shares and Private Placement Warrants,” to our officers and directors and other persons or entities affiliated with sponsor) and
they will not be redeemable by us so long as they are held by our sponsor or its permitted transferees. Otherwise, the private placement
warrants have terms and provisions that are identical to those of the warrants sold as part of the units in our initial public offering.
If the private placement warrants are held by holders other than our sponsor or its permitted transferees, the private placement warrants
will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the units sold in our initial public
offering.


 


Except as described under “— Redemption
of warrants when the price per ordinary share equals or exceeds $10.00,” if holders of the private placement warrants elect to exercise
them on a cashless basis, they would pay the exercise price by surrendering his, her or its warrants for that number of ordinary shares
equal to the quotient obtained by dividing (x) the product of the number of ordinary shares underlying the warrants, multiplied by
the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair
market value. The “fair market value” shall mean the average last reported sale price of the ordinary shares for the 10 trading
days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. The reason
that we have agreed that these warrants will be exercisable on a cashless basis so long as they are held by our sponsor and permitted
transferees is because it is not known at this time whether they will be affiliated with us following a business combination. If our sponsor
remains affiliated with us, its ability to sell our securities in the open market will be significantly limited. Even during such periods
of time when insiders will be permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession
of material non-public information. Accordingly, unlike public shareholders who could exercise their warrants and sell the ordinary
shares received upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly
restricted from selling such securities. As a result, we believe that allowing the holders to exercise such warrants on a cashless basis
is appropriate.


 


In order to finance transaction costs in connection
with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may,
but are not obligated to, loan us funds as may be required. Up to $1,500,000 of such loans may be convertible into warrants at a price
of $1.00 per warrant at the option of the lender. Such warrants would be identical to the private placement warrants.


 


Our sponsor has agreed, and any of its assignees
or transferees will agree, not to transfer, assign or sell any of the private placement warrants (including the ordinary shares issuable
upon exercise of any of these warrants) until the date that is 30 days after the date we complete our initial business combination,
except that, among other limited exceptions as described under “Principal Shareholders — Transfer Restrictions on
Founder Shares and Private Placement Warrants,” made to our officers and directors and other persons or entities affiliated with
our sponsor.


 






    12


     


    

 


Dividends


 


We have not paid any cash dividends on our ordinary
shares to date and do not intend to pay cash dividends prior to the completion of an initial business combination. The payment of cash
dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions
subsequent to completion of an initial business combination. The payment of any cash dividends subsequent to an initial business combination
will be within the discretion of our board of directors at such time. In addition, our board of directors is not currently contemplating
and does not anticipate declaring any share dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to
declare dividends may be limited by restrictive covenants we may agree to in connection therewith.


 


Our Transfer Agent and Warrant Agent


 


The transfer agent for our ordinary shares and warrant
agent for our warrants is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer &
Trust Company in its roles as transfer agent and warrant agent, and its agents and each of its shareholders, directors, officers and employees
against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any liability
due to any gross negligence or intentional misconduct of the indemnified person or entity.


 


Amendments to our Amended and Restated Memorandum and Articles of
Association


 


As set forth in the amended and restated memorandum
and articles of association, the objects for which we are established are unrestricted and we shall have full power and authority to carry
out any object not prohibited by the Companies Act or as the same may be revised from time to time, or any other law of the British Virgin
Islands.


 


Our amended and restated memorandum and articles
of association contain certain requirements and restrictions relating to our initial public offering that will apply to us until the consummation
of our initial business combination. These provisions, and those dealing with the rights attaching to our ordinary shares, cannot be amended
prior to our initial business combination without the approval of a resolution passed at a meeting by shareholders owning 65% of the issued
and outstanding shares that are present and voting at such meeting.


 


Our sponsor, officers and directors have agreed,
each pursuant to a written letter agreement with us, that they will not propose any amendment to our amended and restated memorandum and
articles of association that would affect the substance or timing of our obligation to redeem 100% of our public shares if we do not complete
our initial business combination by August 10, 2022, unless we provide our public shareholders with the opportunity to redeem their ordinary
shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in
the trust account (less any interest released to us for taxes, if any), divided by the number of then outstanding public shares.


 


Specifically, our amended and restated memorandum
and articles of association provide, among other things, that:


 


		●	if we are unable to consummate our initial business combination
by August 10, 2022, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible
but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the trust account, including any amounts representing interest earned on the trust account not previously released
to us to pay our taxes, if any (less $100,000 which we may reserve for expenses of our liquidation or dissolution), divided by the number
of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including
the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably
possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, proceed to commence
a voluntary liquidation and thereby a formal dissolution of the company, subject in each case to our obligations to provide for claims
of creditors and the requirements of the laws of the British Virgin Islands and other applicable law;



 


		●	after the consummation of our initial public offering and
prior to our initial business combination, we may not issue additional shares that would entitle the holders thereof to (i) receive
funds from the trust account or (ii) vote on any initial business combination;



 






    13


     


    

 


		●	although we do not currently intend to enter into an initial
business combination with a target business that is affiliated with our sponsor, our directors or officers, we are not prohibited from
doing so. In the event we enter into such a transaction, we, or a committee of independent directors, will obtain an opinion from an
independent investment banking firm that is a member of FINRA or from an independent accounting firm that such an initial business combination
is fair to our shareholders from a financial point of view;



 


		●	if a shareholder vote on our initial business combination
is not required by law or Nasdaq and we do not decide to hold a shareholder vote for business or other reasons, we shall offer to redeem
our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents
with the SEC prior to consummating our initial business combination which contain substantially the same financial and other information
about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act;



 


		●	we will not effectuate our initial business combination with
another blank check company or a similar company with nominal operations; and



 


		●	our initial business combination must occur with one or more
target businesses that together have an aggregate fair market value of at least 80% of the assets held in the trust account (excluding
the deferred underwriting commissions and taxes payable, if any, on the income accrued on the trust account) at the time of the agreement
to enter into the initial business combination.



 


In addition, our amended and restated memorandum
and articles of association provide that under no circumstances will we redeem our public shares in an amount that would cause our net
tangible assets to be less than $5,000,001 prior to or upon the consummation of our initial business combination. This notwithstanding,
if the effect of any proposed amendment, if adopted, would be either to (i) reduce the amount in the trust account available to redeeming
shareholders to less than $10.00 per share, or (ii) delay the date on which a public shareholder could otherwise redeem shares for
such per share amount in the trust account, we will provide a right for dissenting public shareholders to redeem public shares if such
an amendment is approved.


 


Our sponsor, officers and directors have agreed,
each pursuant to a written agreement with us, that they will not propose any amendment to our amended and restated memorandum and articles
of association that would affect the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our
initial business combination by August 10, 2022, unless we provide our public shareholders with the opportunity to redeem their ordinary
shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in
the trust account (less any interest previously released to us to pay taxes, if any, and less up to $100,000 in interest reserved for
expenses in connection with our dissolution), divided by the number of then outstanding public shares. These agreements are contained
in letter agreements that we have entered into with our sponsor, officers and directors.


 


Changes in Authorized Shares


 


We are authorized to issue an unlimited number of
shares which will have rights, privileges, restrictions and conditions attaching to them as the shares in issue. We may by resolution
of directors or shareholders:


 


		●	consolidate and divide all or any of our unissued authorized
shares into shares of larger or smaller amount than our existing shares;



 


		●	cancel any ordinary shares which, at the date of the passing
of the resolution, have not been taken or agreed to be taken by any person; or



 


		●	create new classes of shares with preferences to be determined
by resolution of the board of directors to amend the amended and restated memorandum and articles of association to create new classes
of shares with such preferences at the time of authorization, although any such new classes of shares, with the exception of the preferred
shares, may only be created with prior shareholder approval.



 






    14


     


    

 


Pre-emption Rights


 


There are no pre-emption rights applicable
to the issuance of new shares under our amended and restated memorandum and articles of association.


 


Variation of Rights of Shares


 


As permitted by the Companies Act and our memorandum
of association, we may vary the rights attached to any class of shares only with: (i) in the case of the ordinary shares prior to
our initial business combination, the consent of not less than 65% of the votes of such shares who are in attendance and vote at a meeting,
or (ii) in the case of the preferred shares, 50% of the votes of shareholders who being so entitled attend and vote at a meeting
of such shares, except where (in each case) a greater majority is required under our amended and restated memorandum and articles of association
or the Companies Act, provided that that for these purposes the creation, designation or issue of preferred shares with rights and privileges
ranking in priority to an existing class of shares is deemed not to be a variation of the rights of such existing class and may in
accordance with our amended and restated memorandum and articles of association be effected by resolution of directors without shareholder
approval.


 


Securities Eligible for Future Sale


 


As of the date of this Report, there were 31,750,000
ordinary shares outstanding. Of these shares, the 25,000,000 ordinary shares sold in our initial public offering are freely tradable without
restriction or further registration under the Securities Act, except for any shares purchased by one of our affiliates within the meaning
of Rule 144 under the Securities Act. All of the remaining 6,750,000 founder shares and all 6,750,000 private placement warrants
are restricted securities under Rule 144, in that they were issued in private transactions not involving a public offering, and are subject
to transfer restrictions as more fully described in our final prospectus.


 


Rule 144


 


Pursuant to Rule 144, a person who has beneficially
owned restricted ordinary shares or warrants for at least six months would be entitled to sell their securities provided that (i) such
person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we
are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required
reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file
reports) preceding the sale.


 


Persons who have beneficially owned restricted ordinary
shares or warrants for at least six months but who are our affiliates at the time of, or at any time during the three months preceding,
a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period
only a number of securities that does not exceed the greater of:


 


		●	1% of the total number of ordinary shares then outstanding,
or 317,500 shares as of the date of the Report; or



 


		●	the average weekly reported trading volume of the ordinary
shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.



 


Sales by our affiliates under Rule 144 are
also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.


 


Restrictions on the Use of Rule 144 by Shell Companies or Former
Shell Companies


 


Rule 144 is not available for the resale of
securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at
any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following
conditions are met:


 


		●	the issuer of the securities that was formerly a shell company
has ceased to be a shell company;



 


		●	the issuer of the securities is subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act;



 






    15


     


    

 


		●	the issuer of the securities has filed all Exchange Act reports
and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required
to file such reports and materials), other than Current Reports on Form 8-K; and



 


		●	at least one year has elapsed from the time that the issuer
filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.



 


As a result, our sponsor will be able to sell its
founder shares and private placement warrants, as applicable, pursuant to Rule 144 without registration one year after we have completed
our initial business combination.


 


Registration Rights


 


The holders of the founder shares, private placement
warrants and warrants that may be issued upon conversion of working capital loans (and any ordinary shares issuable upon the exercise
of the private placement warrants and warrants that may be issued upon conversion of working capital loans) are entitled to registration
rights pursuant to a registration rights agreement requiring us to register such securities for resale. The holders of the majority of
these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition,
the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the
completion of our initial business combination and rights to require us to register for resale such securities pursuant to Rule 415
under the Securities Act. However, the registration rights agreement provides that we will not permit any registration statement filed
under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case
of the founder shares, one year after the date of the completion of our initial business combination or earlier if, subsequent to our
initial business combination, the last reported sale price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for
share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing
at least 150 days after our initial business combination, or (y) we consummate a subsequent liquidation, merger, stock exchange
or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities
or other property, and (ii) in the case of the private placement warrants and the respective ordinary shares underlying such warrants,
30 days after the completion of our initial business combination. We will bear the expenses incurred in connection with the filing
of any such registration statements.


 


Pursuant to the forward purchase agreement, we have
agreed to use our commercially reasonable efforts (i) to file within 30 days after the closing of the initial business combination
a registration statement with the SEC for a secondary offering of the forward purchase shares and the forward purchase warrants (and underlying
ordinary shares), (ii) to cause such registration statement to be declared effective promptly thereafter but in no event later than
sixty (60) days after the initial filing, (iii) to maintain the effectiveness of such registration statement until the earliest of
(A) the date on our sponsor or its assignees cease to hold the securities covered thereby and (B) the date all of the securities
covered thereby can be sold publicly without restriction or limitation under Rule 144 under the Securities Act and (iv) after
such registration statement is declared effective, cause us to conduct firm commitment underwritten offerings, subject to certain limitations.
In addition, the forward purchase agreement provides for “piggy-back” registration rights to the holders of forward purchase
securities to include their securities in other registration statements filed by us.


 






    16


     


    

 


In connection with the proposed business combination
with Nexters Global Ltd. (“Nexters”), Nexters Inc., a British Virgin Islands business company (“Pubco”), our sponsor
and three current significant shareholders of Nexters Global (collectively, the “Holders”) will enter into a new registration
rights agreement (the “New Registration Rights Agreement”), pursuant to which, among other things, subject to certain requirements
and customary conditions, including with regard to the number of demand rights that may be exercised, the Holders may demand at any time
or from time to time, that Pubco file a registration statement with the SEC to register the securities of Pubco held by such Holders.
The New Registration Rights Agreement will also provide the Holders with “piggy-back” registration rights, subject to certain
requirements and customary conditions. The foregoing description of the New Registration Rights Agreement is qualified in its entirety
by reference to the full text of the form of the New Registration Rights Agreement, a copy of which is included as Exhibit A to the Business
Combination Agreement filed as an exhibit to this Report.


 


On January 31, 2021, we, Pubco and the sponsor entered
into an amended and restated forward purchase agreement (the “A&R Forward Purchase Agreement”). Pursuant to the A&R
Forward Purchase Agreement, Pubco has no obligation to register or qualify the Pubco forward purchase securities, or any Pubco ordinary
shares into which the Pubco forward purchase securities may be converted into or exercised for, for resale, except pursuant to the New
Registration Rights Agreement.


 


Listing of Securities


 


Our units, ordinary shares and warrants are listed
on Nasdaq under the symbols “KSMTU,” “KSMT” and “KSMTW,” respectively.


 


 


17